Prime Medicine reports Q3 net loss of $50.7M, cash runway through end 2024; provides pipeline updates

Prime Medicine, Inc.

2023-Q3 EPS reported -$1.46

R&D expenses $41.0M (up 64% YoY); G&A $10.5M (up 59%); net loss widened to $50.7M from $29.4M.
Cash, equivalents, and investments $178.8M as of Sept 30, 2023, down from $307.4M at Dec 31, 2022.
FDA granted Rare Pediatric Drug designation for PM359 (CGD); IND-enabling studies started, IND filing planned for 2024.
Preclinical data showed up to 50% liver editing in NHPs for GSD1b and up to 70% correction in photoreceptors for retinitis pigmentosa.
U.S. PTO issued third patent covering Prime Editing systems with PEgRNA, Prime Editor protein, and optionally a recombinase.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Prime Medicine, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 3, 2023, Prime Medicine, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-036706

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.